Skip to content

Author

D. Montani

We have 2 of 84 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sotatercept improves echocardiographic risk stratification in pulmonary arterial hypertension: real-world data from the french early access program

Management of pulmonary arterial hypertension (PAH) is guided by multiparametric risk assessment, integrating clinical, biological, imaging, and hemodynamic parameters. Echocardiographic low-risk features include right atrial (RA) area <18 cm², TAPSE/PASP ratio >0.32 mm/mmHg, and absence of pericardial effusion....

M. El Blidi, T. Duval, E. Artaud-Macari et al. · 0 citations
Open access Oct 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pre-capillary pulmonary hypertension (PH), preclinical data suggest SGLT2i may improve right ventricular (RV) function through metabolic modulation, reduced perivascular inflammation, and inhibition of vascular remodelin...

M. Ersboll, J. Kjaergaard, F. Gustafsson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.